Clinical Trials

272 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04085276 2026-04-16

TORCHLIGHT

Phase 3 Completed

531 enrolled

Triple Negative Breast Neoplasms

NCT04421963 2026-04-16

ROSY-O

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04829539 2026-04-16

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment

Other hematologic neoplasm

400 enrolled

Hematologic Neoplasms

NCT05256225 2026-04-16

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT05317416 2026-04-16

MagnetisMM-7

854 enrolled

Plasma cell

Hematologic Diseases, Multiple Myeloma

NCT05317858 2026-04-16

LIMITLESS

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05450692 2026-04-16

LATIFY

594 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05580562 2026-04-16

ACTION

510 enrolled

CNS

Glioma

NCT05587296 2026-04-16

OASIS-4

474 enrolled 14 charts

Hot Flashes

NCT05642611 2026-04-16

ICE COMPRESS

777 enrolled

Other solid neoplasm

Malignant Solid Neoplasm

NCT05659381 2026-04-16

HOTT

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05939414 2026-04-16

PSMA-DC

450 enrolled

Oligometastatic Prostate Cancer (OMPC)

NCT06058377 2026-04-16

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06073821 2026-04-16

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

LymphoidOther hematologic neoplasm

652 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06439225 2026-04-16

OPTION-DDR

236 enrolled

Prostatic Neoplasms

NCT06467357 2026-04-16

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT06568172 2026-04-16

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

DermatologicHead & NeckSarcoma

420 enrolled

Eyelid Squamous Cell Carcinoma

NCT06629779 2026-04-16

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06717347 2026-04-16

MK-2140-010

1,046 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06746116 2026-04-16

DUoENDE

45 enrolled

Endometrial Neoplasms

NCT06784752 2026-04-16

NETTER-3

EndocrineGastrointestinalLymphoidNET

240 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT06824467 2026-04-16

TroFuse-022

770 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06846671 2026-04-16

CaDAnCe-302

LymphoidOther hematologic neoplasm

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07005128 2026-04-16

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07061977 2026-04-16

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07085767 2026-04-16

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT07100730 2026-04-16

IPAX BrIGHT

50 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

NCT07152821 2026-04-16

BATTMAN

834 enrolled

Colorectal Neoplasms

NCT07185997 2026-04-16

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

480 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT07213674 2026-04-16

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT07214779 2026-04-16

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT07284849 2026-04-16

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

700 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT07318558 2026-04-16

TroFuse-021

900 enrolled

Ovarian Neoplasms

NCT07409272 2026-04-16

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

614 enrolled

Pancreatic Neoplasms

NCT07504458 2026-04-16

QUATRO-APL

Other hematologic neoplasm

150 enrolled

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Promyelocytic, Acute, Hematologic Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

364 enrolled

Triple Negative Breast Neoplasms

NCT01630733 2026-04-15

ENSPIRIT

Phase 3 Completed

664 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03520686 2026-04-15

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03525873 2026-04-15

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

212 enrolled

Neoplasm Metastasis, Recurrence

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT03778957 2026-04-15

EMERALD-1

724 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03967977 2026-04-15

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT04267848 2026-04-15

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04269902 2026-04-15

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study